Roquefort Therapeutics PLC Board Appointment (2233H)
April 05 2022 - 2:01AM
UK Regulatory
TIDMROQ
RNS Number : 2233H
Roquefort Therapeutics PLC
05 April 2022
5 April 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Board Appointment
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, is pleased to announce the appointment of Ms Jean Duvall as
a Non-Executive Director, and the resignation of Mr Mark Rollins as
Non-Executive Director.
Ms Duvall is a highly accomplished individual in the biotech and
pharma sector, with over 25 years experience in executive roles in
the industry. During this time, Ms Duvall acted for Ferring
Pharmaceuticals, as one of the Executive Board Members who built
the company from a US$700 million to US$2 billion in revenue.
During her time at Ferring, Ms Duvall led or co-led over 10
transactions and had legal oversight on over 25 transactions. Ms
Duvall has a significant track record in corporate development
having led multiple successful M&A, divestment and licensing
deals throughout her career. During her time at Elan Corporation,
Ms Duvall was responsible for the launch and commercialisation of
Tysabri, a treatment for multiple sclerosis and Crohn's disease,
outside of the US in collaboration with Biogen Idec. She previously
had the role of General Counsel at Elan and was legal lead,
negotiating the divestment of over $2bn in assets.
Additionally, she has co-founded and led biopharma start-ups
including Trizell and Amzell, resulting in multiple products having
successful phase 2 and 3 clinical studies. Trizell in particular
received several multi-billion dollar offers for its lead oncology
gene therapy product, Adstiladrin, which is now in the registration
phase.
Ms Duvall is currently CEO and Co-Founder of ReproNovo, a
women's health and reproductive medicine company focussing on
R&D and manufacturing with potential products entering phase 2
and phase 1. Additionally, Ms Duvall is a Non Executive Board
member of an AIM listed life sciences company, Ondine Biomedical
Inc., a company focused on photodisinfection-based therapies to
prevent and treat a broad spectrum of infections, including those
caused by drug-resistant pathogens.
Stephen West, Roquefort Therapeutics Executive Chairman,
commented:
"It is with great pleasure that I welcome Jean Duvall to the
Company's Board, where she will provide invaluable insight and
expertise in helping Roquefort Therapeutics develop and progress
our preclinical programmes. Jean's track record speaks for itself
and her knowledge and experience in drug development,
commercialising programmes and value creation in life sciences will
be a valuable asset to our team. Roquefort Therapeutics is putting
together a top team in place and we look to the future with
optimism.
"I would also like to thank Mark Rollins for his contribution
during the early stages of Roquefort Therapeutics, which is now
well positioned to continue its next phase of development with
Jean's addition to the Board."
Commenting on her appointment, Roquefort Therapeutics NED Jean
Duvall said:
"I am excited to join the Board of Roquefort Therapeutics. The
therapeutic potential of Midkine is very interesting and I believe
has the potential to meet a number of indications of unmet needs in
major markets. I look forward to working with the team on
developing its preclinical drug programme in cancer and to
exploring the many other indications blocking midkine could help
treat."
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is focused on
developing first in class Midkine inhibiting RNA therapeutics drugs
for the treatment of cancer, chronic inflammation, autoimmune
disorder and COVID-19. Recent progress within mRNA therapeutics has
led to a reduction in drug development timelines and costs,
increasing the chance of early value creation.
Through extensive research resulting in validation through
publication in over 1,000 scientific publications, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of significant unmet need. Roquefort Therapeutics holds
the largest global IP portfolio on Midkine. The Midkine blocking
drug development markets have significant global market potential
(in the multi-billion dollars). Roquefort Therapeutics's
pre-clinical programme is currently underway with an initial focus
on cancer treatment aiming to improve immunotherapy responses.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAGZGGDNDKGZZM
(END) Dow Jones Newswires
April 05, 2022 02:01 ET (06:01 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024